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We conducted a randomized controlled trial to compare the
quality of life of 52 patients undergoing nocturnal hemodialysis
and conventional hemodialysis. Quality of life was measured
using a number of established methods including the Kidney
Disease Quality of Life Short Form and the preference-based
Euroqol EQ-5D questionnaire (whose scores varied from 0 to 1).
The primary outcome was a change in the Euroqol EQ-5D index
scores between baseline and 6 months. We performed
additional analyses comparing change in quality of life from
pre-randomization (when patients were unaware of treatment
allocation) to 6 months. Other analyses considered the impact
of nocturnal hemodialysis on four pre-selected Kidney Disease
Quality of Life Short Form domains, and the longer term
impact of nocturnal hemodialysis on quality of life. Compared
with conventional hemodialysis, nocturnal hemodialysis
increased Euroqol-EQ-5D index scores by 0.05, which was not
significantly different from baseline. When six-month values
were compared with pre-randomization values rather than
baseline values, the between group difference was larger (0.12)
though it was still not statistically significant (P¼ .06).
Nocturnal hemodialysis was associated with clinically and
statistically significant improvements in selected kidney-
specific quality of life domains (P¼ .01 for effects of kidney
disease; P¼ .02 for burden of kidney disease). Our primary
quality of life analysis did not demonstrate a statistically
significant change between nocturnal hemodialysis and
conventional hemodialysis, though statistically significant and
clinically important changes in some secondary kidney-disease-
specific measures were observed.
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Despite advances in dialysis therapy, mortality and morbidity
remain high, and significant deficits in quality of life exist for
patients with end-stage renal disease.1 Conventional hemo-
dialysis fails to normalize the majority of the numerous
complex metabolic and physiological abnormalities present
in the ‘uremic’ state, and is a time-consuming and intrusive
therapy.2–4
Nocturnal hemodialysis, a technique first developed in
the 1970s, has received renewed attention, given its potential
for overcoming some of the limitations of conventional
hemodialysis.2,5 In nocturnal hemodialysis, patients
perform dialysis at home three to six nights per week while
sleeping. Case–control and cohort studies suggest that
nocturnal hemodialysis may improve left ventricular
mass,2,6,7 blood pressure, and quality of life.2,8,9 Despite
design limitations, these studies also suggest quality of life
improvements for conventional hemodialysis patients shortly
after changing to nocturnal hemodialysis, with increased
energy, strength and endurance, and fewer dietary
restrictions.2,8,9 However, given that nocturnal hemodialysis
is time consuming, complicated, and intrusive, it is also
possible that nocturnal hemodialysis could negatively impact
quality of life.2
We recently reported the results of a randomized trial
comparing nocturnal hemodialysis and conventional hemo-
dialysis on change in left ventricular mass and other
outcomes.10 Compared with conventional hemodialysis,
nocturnal hemodialysis patients experienced an improvement
in one measure of overall quality of life using the Euroqol
EQ-5D, and statistically significant improvements were
observed in selected facets of kidney-disease-specific quality
of life measures.
In this article we expand on these results,10 and describe in
detail the impact of nocturnal hemodialysis on kidney-
disease-specific and generic quality of life measures. To
determine the impact of nocturnal hemodialysis on longer-
term quality of life, we also report quality of life in study
participants during extended follow-up after completion of
the trial.
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RESULTS
Baseline characteristics
A total of 69 patients expressed an interest in nocturnal
hemodialysis. A total of 17 patients did not meet inclusion
criteria or fulfilled exclusion criteria and 1 patient refused
all study-related procedures after providing consent
(Figure 1). Therefore, the intention-to-treat population
included 26 patients randomized to nocturnal hemodialysis
and 25 patients randomized to conventional hemodialysis.
During the 6-month intervention period, 5 patients
either died, received a transplant or did not receive the
modality to which they were randomized (Figure 1); these 5
patients were included in the intent-to-treat population.
Baseline characteristics between the groups were similar
(Table 1). Patients enrolled in this study were, on average,
younger than ‘typical’ North American dialysis patients,
though comorbid conditions including diabetes and ischemic
heart disease were common (Table 1). For the nocturnal
hemodialysis patients, the mean number of weeks from
randomization to baseline was 14.3 (s.d. 9.4); for patients
randomized to conventional hemodialysis, the mean
number of weeks from randomization to baseline was 10.0
(s.d. 6.0).
Quality of life was similar between the two groups
just before randomization (Table 2), though there were
significant differences in 2 of 19 individual Kidney
Disease Quality of Life and Short Form 36 domains,
‘sleep’ and ‘role—emotional’, both favoring nocturnal
hemodialysis.
Quality of life outcomes
Euroqol EQ-5D. Nocturnal hemodialysis did not improve
the change in EQ-5D index scores from baseline to 6 months
compared with conventional hemodialysis (between-group
difference, 0.05; 95% confidence interval (CI), 0.07 to 0.17;
P¼ 0.43) (Figure 2a). When 6-month values were compared
with prerandomization values, rather than baseline values,
the between-group difference was larger (0.12 for the change;
95% CI, 0.005 to 0.25; P¼ 0.06) (Figure 2a), but remained
nonsignificant. Similar findings were noted for the EQ-5D
visual analog score; no significant difference between
nocturnal hemodialysis and conventional hemodialysis was
observed when comparing baseline and 6-month values
(P¼ 0.90), but a clinically significant 10-point change was
noted when comparing scores obtained prerandomization
with 6-month values (P¼ 0.03) (Figure 2b).
Kidney Disease Quality of Life: Short Form
In analyses that focused on the prespecified kidney-disease-
specific domains, there was a statistically significant im-
provement between baseline and 6 months in the domains
‘effects of kidney disease’ and ‘burden of kidney disease’
comparing nocturnal hemodialysis compared with conven-
tional hemodialysis (Figure 3).
Short Form 36
No clinically or statistically significant differences were noted in
the physical and mental composite scores comparing 6-month
and baseline scores between the nocturnal hemodialysis
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Figure 1 | Trial flow.
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and conventional hemodialysis groups. There were small
non-significant changes in several Short Form 36 domains
(Table 3).
For all quality of life analyses, similar results were obtained
based on observed cases only and per-protocol analyses.
Moreover, these results did not appreciably change when
adjusted for baseline quality of life values or baseline dialysis
modality.
Quality of life measures over extended follow-up
After completion of the 6-month study period, all patients
who were still alive and treated with dialysis agreed to
extended follow-up. Quality of life measures were available
for all 34 of these individuals (Figure 1). The median time on
nocturnal hemodialysis for patients randomized to nocturnal
hemodialysis that remained on nocturnal hemodialysis, and
patients switching from conventional hemodialysis to
nocturnal hemodialysis was 30, and 23 months, respectively.
Given frequent crossover after the 6-month study visit,
follow-up quality of life data is provided for the following
four groups: patients randomized to nocturnal hemodialysis
who remained on nocturnal hemodialysis (n¼ 14); patients
randomized to nocturnal hemodialysis who returned to
conventional hemodialysis (n¼ 3); patients randomized to
conventional hemodialysis who remained on conventional
hemodialysis (n¼ 10) and; patients randomized to conven-
tional hemodialysis who switched to nocturnal hemodialysis
(n¼ 7) (Figure 1). Data are provided for both the EQ-5D
index score and the 4 Kidney Disease Quality of Life—Short
Form domains of interest. Aside from the small number of
patients returning from nocturnal hemodialysis to conven-
tional hemodialysis (typically due to the inability to manage
Table 1 | Patient baseline characteristics at the time of
baseline examination by dialysis modality*
Characteristic
Nocturnal
hemodialysis
(n=26)
Conventional
hemodialysis
(n=25)
Age (years) 55.1±12.4 53.1±13.4
Male gender (%) 18 (69) 14 (56)
Caucasian (%) 23 (88) 21 (84)
Time on dialysis (years) 5.5±5.3 4.8±3.8
Median (interquartile range) 3 (1–9) 4 (2–6)
Baseline dialysis modality (%)
In-center hemodialysis 18 (69) 13 (52)
Home or self-care hemodialysis 2 (8) 5 (20)
Home hemodialysis 6 (23) 7 (28)
Cause of ESRD (%)
Diabetic nephropathy 7 (27) 8 (32)
Hypertension/vascular 2 (8) 2 (8)
Glomerulonephritis 5 (19) 8 (32)
Polycystic kidney disease 3 (12) 1 (4)
Urologic 3 (12) 3 (12)
Other 6 (24) 3 (12)
Comorbid illnesses (%)
Ischemic heart disease 10 (38) 10 (40)
Congestive heart failure 6 (23) 5 (20)
Peripheral vascular disease 4 (15) 4 (16)
Cerebrovascular disease 5 (19) 3 (12)
Diabetes mellitus 10 (38) 11 (44)
Time from randomization to
baseline visit (weeks)
14.3±9.4 10.0±6.0
ESRD, end-stage renal disease.
Values (±) are means±standard deviation.
*P40.05 for all comparisons between nocturnal hemodialysis and conventional
hemodialysis groups.
Table 2 | Prerandomization quality of life measures
All patients Conventional hemodialysis Nocturnal hemodialysis
Quality of life domain n=51 (95% CI) n=25 (95% CI) n=26 (95% CI)
EQ-5D visual analog scale 58.9 (53.4, 64.4) 61.6 (53.3, 69.9) 56.3 (48.6, 64.1)
EQ-5D index score 0.694 (0.626, 0.762) 0.705 (0.611, 0.800) 0.683 (0.579, 0.786)
Kidney disease quality of life ‘kidney-disease’-targeted scales
Symptom/problems 69.7 (64.7, 74.6) 65.4 (57.5, 73.4) 73.8 (67.6, 79.9)
Effects of kidney disease 48.4 (42.1, 54.7) 42.0 (32.9, 51.1) 54.6 (45.9, 63.2)
Burden of kidney disease 30.5 (23.1, 37.8) 25.4 (17.1, 33.7) 35.3 (23.1, 47.6)
Sleep 52.7 (47.0, 58.4) 46.3 (36.5, 56.1) 58.8 (53.2, 64.5)a
Short form 36 health scales
Physical functioning 51.4 (43.6, 59.3) 53.3 (43.7, 62.9) 49.6 (36.7, 62.6)
Role—physical 25.5 (14.9, 36.1) 21.0 (6.8, 35.2) 29.8 (13.4, 46.2)
Bodily pain 54.4 (46.2, 62.7) 48.8 (37.7, 59.9) 59.9 (47.4, 72.3)
General health 33.4 (27.0, 39.9) 32.0 (23.3, 40.7) 34.8 (24.8, 44.8)
Mental health 67.5 (61.4, 73.5) 63.4 (54.6, 72.1) 71.4 (62.7, 80.1)
Role—emotional 58.8 (46.7, 70.9) 41.3 (23.9, 58.8) 75.6 (60.6, 90.7)b
Social functioning 59.1 (51.1, 67.1) 54.5 (44.5, 64.5) 63.5 (50.6, 76.3)
Vitality 38.3 (31.9, 44.8) 36.0 (27.9, 44.1) 40.6 (30.2, 51.0)
Physical composite score 32.2 (28.9, 35.5) 32.7 (29.0, 36.5) 31.7 (26.1, 37.4)
Mental composite score 46.1 (42.7, 49.5) 42.1 (37.2, 47.0) 50.0 (45.4, 54.5)c
aP=0.02.
bP=0.003.
cP=0.02.
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their own dialysis at home due to illness), quality of life was
relatively stable in the small numbers of patients who
remained on nocturnal hemodialysis, conventional hemo-
dialysis, or who switched from conventional hemodialysis to
nocturnal hemodialysis (Figure 4a and b).
Multilevel modeling
Results from the mixed effects model demonstrated no
significant association between modality type and EQ-5D
index (P¼ 0.77) over the study period and during the
extended observational period. The results of these models
were unchanged when using imputed zero values for
deceased patients or censoring deceased patients.
DISCUSSION
In this randomized controlled trial comparing nocturnal
hemodialysis with conventional hemodialysis, we found no
difference in our a priori primary quality of life measure
comparing change from baseline to 6 months, but noted
statistically and clinically significant improvements in two of
four kidney-specific measures of quality of life. EQ-5D scores
deteriorated between prerandomization and 6 months in
patients randomized to conventional hemodialysis, and were
maintained or increased slightly in patients randomized to
nocturnal hemodialysis over the 6-month study period,
resulting in highly clinically significant differences in EQ-5D
index scores when comparing 6-month and prerandomiza-
tion scores. Notably, quality of life domains which assess
‘burden of kidney disease’ showed a significant improvement
after conversion to nocturnal hemodialysis, despite the fact
that dialysis became daily and required substantial patient
effort and involvement.
All patients who consented to enroll in this study were
willing to perform nocturnal hemodialysis—it is likely that
their interest stemmed from either a desire to perform a
novel dialysis procedure that was reported to improve their
health, or because they felt that the logistics of nighttime
dialysis would be conducive to their lifestyle. As such, it is
possible that the change in the EQ-5D index scores noted
between ‘randomization’ and baseline visits for both the
nocturnal hemodialysis and conventional hemodialysis
groups may have represented an artificial anticipatory effect
rather than a true benefit of nocturnal hemodialysis per se
captured by the subjective nature of ‘overall’ quality of life
measures. These results (a slight increase in the quality of life
in nocturnal hemodialysis patients and a reduction in quality
of life in control patients) were also noted in a previous
nonrandomized report11 and warrant further investigation.
The differences in quality of life between the nocturnal
hemodialysis and conventional hemodialysis groups ap-
peared to be maintained during extended follow-up,
although the separation between the EQ-5D index scores
and preselected Kidney Disease Quality of Life domains
appeared to diminish over time. The fact that these subjective
quality of life measures (that is the EQ-5D index and visual
analog scores) did not return to ‘prerandomization’ levels
0.85
0.75
0.65
0.55
0.45
n=51 n=51
Prerandomization Baseline Six months
n=48
Nocturnal HD Conventional HD
* Comparing change in EQ-5D index score from randomization to 6 months, for NHD vs CHD
* Comparing change in EQ-5D index score from randomization to 6 months, for NHD vs CHD
† Comparing change in EQ-5D index score from baseline to 6 months, for NHD vs CHD
† Comparing change in EQ-5D index score from baseline to 6 months, for NHD vs CHD
P=0.03 *
95% upper Cl
95% upper Cl
P=0.90†
P=0.43†
95% lower Cl
95% lower Cl
n=51 n=51 n=48
75
65
55
45
Baseline Six monthsPre-randomization
EQ
-5
D 
VA
S 
sc
or
es
Nocturnal HD Conventional HD
EQ
-5
D 
ind
ex
 sc
or
es
P=0.06*
Figure 2 | In-trial EQ-5D scores. (a) EQ-5D index scores for
nocturnal hemodialysis and conventional hemodialysis during the
RCT. (b) EQ-5D visual analog scores for nocturnal hemodialysis
and conventional hemodialysis during the RCT.
16
14
12
10
8
6
4
2
−2
−4
0
Symptoms /
problems
Effects of
kidney disease
Burden of
kidney disease
Sleep
* Comparing change in KDQOL scores from baseline to 6 months, for NHD vs CHD
Ch
an
ge
 in
 K
DQ
OL
 sc
or
es
P=0.33*
P=0.01*
P=0.02*
P=0.49*
Nocturnal HD Conventional HD
Figure 3 | The change in relevant Kidney-Disease-Specific
Quality of Life Domains comparing 6 months and study
baseline.
Kidney International (2009) 75, 542–549 545
BJ Manns et al.: Quality of life in nocturnal hemodialysis o r i g i n a l a r t i c l e
after 6 months of exposure to the therapy suggests that some
of this noted difference in these scores at 6 months was due to
the allocated therapy. This hypothesis should be tested by the
ongoing National Institutes of Health-sponsored randomized
trial of frequent home nocturnal dialysis.12
Assuming that the true benefit of nocturnal hemodialysis
is best reflected by the comparison between 6-month and
prerandomization scores, it appears that this difference
would be clinically relevant. For example, Dolan13 define a
clinically significant change in the EQ-5D index score as 0.03,
whereas a change of 10 units in the visual analog score is
considered statistically significant. In comparison, dialysis
patients who receive a kidney transplant experience a mean
increase in utility of 0.13 units14—which is similar to the
(nonsignificant) difference observed between nocturnal
hemodialysis and conventional hemodialysis patients (0.12
units) in the current analysis.
With respect to the other quality of life measures used,
defining what constitutes a ‘clinically significant’ change
continues to be a matter of debate.15,16 Recent work17–19
suggests that a minimally important clinical difference in a
quality of life measure exists if the ‘change’ in the quality of
life domain is 41 standard error measurement. Of interest,
the magnitude of change in the ‘effects of kidney disease’ and
‘burden of kidney disease’ domains (comparing nocturnal
hemodialysis and conventional HD patients) in this study is
between 2.5 and 3 standard error measurement, suggesting
these differences are also clinically significant.
When comparing our results with those of previous
observational studies,2,8,9,20 it is important to note several
methodological problems common to those studies including
small sample size, incomplete reporting of quality of life
measures, and inconsistent use of any type of control group.2
These studies suggest, though, that quality of life improves after
conversion to nocturnal hemodialysis, although the degree and
clinical significance of these changes vary by study.2
There were limitations to this study and the results should
be interpreted within the context of these limitations. First,
the study was powered to detect changes in left ventricular
mass, and thus statistical power was inadequate to detect
clinically significant differences in several of the quality of life
outcome measures. For example, we would have needed 342
patients per group to have 80% power to show a 0.03 unit
change in EQ-5D index scores (the minimally clinically
detectable difference). To show a 0.06 unit change, we would
have required 87 patients per group. Second, quality of life
measures are subjective and we were unable to blind
treatment allocation to patients and the investigators. Data
analysts were blinded and prerandomization quality of life
measures were completed before knowledge of intervention,
thus reducing the potential for bias. Although it is
controversial how best to handle patients who are lost to
follow-up21 due to transplantation and death, our findings
were similar in sensitivity analyses that used several
alternative approaches. Finally, we did not adjust for multiple
comparisons.
Table 3 | Difference in short form 36 scores comparing 6 months and baseline, between nocturnal hemodialysis and
conventional hemodialysis
Quality of life domain
Difference in quality of life
(nocturnal
hemodialysis–conventional HD)
comparing baseline and
6 months (95% CI)
P-value for difference in
quality of life (nocturnal
hemodialysis–conventional
hemodialysis)
Difference in quality of life
(nocturnal
hemodialysis–conventional
hemodialysis) comparing
prerandomization and
6 months (95% CI)
P-value for difference in
quality of life (nocturnal
hemodialysis–conventional
hemodialysis)
Kidney disease quality of life—short form domains of interest
Symptom/problems 3.72 (3.81, 11.24) 0.33 1.04 (8.31, 6.23) 0.77
Effects of kidney disease 8.59 (2.02, 15.16) 0.01 2.58 (4.54, 9.71) 0.47
Burden of kidney disease 9.40 (1.29, 17.52) 0.02 10.70 (2.42, 18.99) 0.01
Sleep 2.61 (10.22, 4.99) 0.49 3.50 (12.66, 5.66) 0.45
Short form 36 health scales
Physical functiona 3.98 (7.54, 15.50) 0.49 1.35 (9.98, 12.67) 0.81
Role—physical 2.08 (17.33, 21.49) 0.83 3.88 (24.15, 16.38) 0.7
Bodily pain 9.04 (5.74, 23.83) 0.22 1.03 (14.77, 12.72) 0.88
General healtha 4.48 (2.82, 11.78) 0.22 12.82 (2.88, 22.77) 0.01
Emotional well-being 5.04 (5.44, 15.52) 0.34 4.78 (6.24, 15.81) 0.39
Role—emotional 4.00 (18.53, 26.53) 0.72 10.46 (35.43, 14.50) 0.4
Social function 4.94 (6.51, 16.39) 0.39 2.92 (9.52, 15.37) 0.64
Vitalitya 5.89 (4.39, 16.18) 0.26 2.82 (8.67, 14.30) 0.62
Short form 36 physical
composite score
1.49 (2.23, 5.21) 0.42 1.24 (3.59, 6.07) 0.61
Short form 36 mental
composite score
2.49 (2.95, 7.94) 0.36 0.71 (5.85, 7.26) 0.83
aPotential Short Form 36 domains of interest, identified a priori.
Note: a ‘positive’ number represents improved quality of life over the course of the randomized trial for nocturnal hemodialysis compared with conventional hemodialysis,
while a negative number represents lower quality of life over the course of the randomized trial for nocturnal hemodialysis compared with conventional hemodialysis.
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In addition to these limitations, this study also has several
important strengths. Although this study is small, it is larger
than previous observational studies of nocturnal hemodia-
lysis.2,8,9,20 Quality of life measures were available for all
patients who were alive and on dialysis at study end and after
significant observational follow-up. Similarly, this is the first
randomized trial of nocturnal hemodialysis, an important
point given that observational data may lead to conclusions
ultimately refuted by randomized trials.
When considering the uncertainties that remain with
respect to the impact of nocturnal hemodialysis on quality of
life in this study, readers should consider that demonstrating
differences in quality of life between dialysis modalities
in randomized trials may be challenging, given that dialysis
treatment impacts quality of life significantly in its own
right. As such, studies comparing quality of life between
different dialysis modalities measure not only the
positive impact (‘benefit’) of the intervention on quality of
life, but also the negative impact (‘intrusiveness’) of the
modality on quality of life. Previous studies have shown
that it is difficult to find patients who are truly indifferent
to which dialysis modality they wish to perform.22
When choosing between available dialysis modalities,
patients should consider how the different therapies will
impact their lifestyle in the context of their individual
circumstances and preferences, as well as the findings of
studies such as this one. If future studies show frequent home
nocturnal hemodialysis to be similar in cost to in-center
hemodialysis, then it would seem reasonable to make
nocturnal hemodialysis an option for motivated patients
who are willing to trade a more demanding therapy for a
potential of improved quality of life.
In conclusion, our primary quality of life analysis did not
demonstrate a statistically significant change between noc-
turnal hemodialysis and conventional hemodialysis. How-
ever, clinically important and statistically significant changes
in some kidney-disease-specific measures were observed
during the trial, and appeared durable over time. The
magnitude of differences in EQ-5D index scores observed in
secondary analyses (if confirmed in adequately powered
randomized trials) would be of substantial clinical signifi-
cance. These findings support the increased use of nocturnal
hemodialysis in selected groups of patients.
MATERIALS AND METHODS
Patients
Detailed methods have been previously reported.10,23 Eligible
patients were actively recruited from 10 hemodialysis units at 2
universities (University of Calgary and University of Alberta) in
Alberta, Canada. Eligible patients were at least 18 years old, receiving
in-center, self-care, or home conventional hemodialysis 3 times
weekly, and interested and willing to train for and commence
nocturnal hemodialysis. Patients were excluded if they lacked the
physical or mental capacity to train for nocturnal hemodialysis.
Ethical approval was obtained at both the University of Calgary and
the University of Alberta.
Study protocol
This was a two-group, parallel-design study. After consent and
before patient’s knowledge of treatment allocation, patients meeting
inclusion/exclusion criteria completed detailed quality of life
questionnaires. Patients were then randomized to either frequent
nocturnal hemodialysis or conventional hemodialysis (Figure 1).
Patients assigned to nocturnal hemodialysis were trained in-center
4–5 times per week for 2–6 weeks, with direct nursing supervision
and monitoring of biochemical parameters. Upon completion of
training, nocturnal hemodialysis was performed at home by the
patient, without remote monitoring, 5–6 nights per week for a
minimum of 6 h per night. The details of the nocturnal hemodialysis
prescription have been provided elsewhere.23 Patients assigned to
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Figure 4 | Quality of life after completion of RCT during
extended followup. (a) EQ-5D index scores during extended
follow-up for patients remaining on nocturnal hemodialysis,
conventional hemodialysis, and those switching from nocturnal
hemodialysis to conventional hemodialysis, or from conventional
hemodialysis to nocturnal hemodialysis. (b) The change in
relevant Kidney-Disease-Specific Quality of Life Domains
comparing May 2007 and RCT completion for patients remaining
on nocturnal hemodialysis, conventional hemodialysis, and those
switching from nocturnal hemodialysis to conventional
hemodialysis, or from conventional hemodialysis to nocturnal
hemodialysis (Note: bars above zero represent improvement in
quality of life comparing May 2007 and RCT completion).
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conventional hemodialysis continued their pre-randomization
dialysis modality with thrice weekly hemodialysis.
Study outcomes, including quality of life, were obtained in all
patients before randomization (before patient knowledge of
treatment allocation) and at baseline and exit visits bracketing the
6-month randomization period (Figure 1). All quality of life
questionnaires were self-administered, completed although the
patients were not receiving dialysis, and asked patients to consider
quality of life over the preceding 2 weeks. Given the nature of the
intervention it was not possible to blind patients and investigators to
the study intervention; however, data analysts were blinded to
treatment allocation. The first patient was enrolled in August 2004
and the last study visit occurred in December 2006.
After completion of the randomized study, patients in the
control group were allowed to train for nocturnal hemodialysis, if
they wished. All participants were invited to enroll in a follow-up
study, with further assessment of quality of life measures undertaken
in May 2007 for all patients who were alive and being treated with
any dialysis modality.
Quality of life measures
Consistent with published guidelines,24,25 quality of life was assessed
using a spectrum of quality of life instruments including the disease-
specific Kidney Disease Quality of Life—Short Form,26–28 a generic
Short Form 36,27,29 and a preference-based EuroQol EQ-5D
questionnaire.13,27
The primary quality of life outcome was change in the EQ-5D
index score, which measures overall quality of life on a scale ranging
from 0.0 (dead) through 1.0 (full health),13,27 and is commonly used
as a measure of ‘overall quality of life’ in dialysis patients.30 This
score focuses on five dimensions: mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression. A minimum increment of
0.03 in the EQ-5D score is considered clinically important as it
corresponds to the smallest coefficient for a change from ‘No
problem’ to ‘Some problems’ within a dimension of the EQ-5D.13
We also considered the EQ-5D visual analog scale score (0–100, with
100 representing perfect health), a more subjective measure of the
patients’ overall quality of life.
The Kidney Disease Quality of Life—Short Form includes
questions targeted at particular health-related concerns for indivi-
duals undergoing dialysis. Scores on each Kidney Disease Quality of
Life—Short Form dimension range from 0 through 100, with higher
scores reflecting better quality of life.26 A priori, we selected 4 out of
11 dimensions that we thought would be most likely affected by
nocturnal hemodialysis (kidney disease-related symptoms/
problems, effects of kidney disease, burden of kidney disease, and sleep).
The generic, nonpreference-based, quality of life profile measure
used in this study was the Short Form 36, which includes eight
multi-item scales describing general quality of life issues.29 Scores on
each dimension can range from 0 to 100, with higher scores
reflecting better quality of life. Although not selected a priori during
the study planning stages, before data analysis we selected domains
which we felt would be most likely affected by nocturnal
hemodialysis: physical function, general health, and vitality.
Exploratory analyses of the remaining domains were performed.
Statistical analysis
The primary quality of life objective of the randomized study was to
evaluate the change in EQ-5D index scores between baseline and 6
months for nocturnal hemodialysis compared with conventional
hemodialysis patients. As quality of life questionnaires are subjective
and may be affected by knowledge of randomization allocation, we
performed additional analyses comparing change in quality of life
values from prerandomization (when patients were not aware of
their treatment allocation) to 6 months. Other analyses considered
the impact of nocturnal hemodialysis on EQ-5D visual analog
scores, the four Kidney Disease Quality of Life—Short Form
domains of interest, as well as Short Form 36 physical and mental
composite scores and individual domains of interest.
The primary analysis used an intention-to-treat approach. A last-
value carried forward approach was used to impute final quality of
life data for patients for whom we did not have 6-month quality of
life data, either because they had died (n¼ 1), or had received a
transplant (n¼ 2).21 Secondary analyses considered an ‘observed
cases’ approach; in this analysis, only patients completing the
6-month study and who provided quality of life questionnaires at
baseline and 6 months were included in the analysis. Finally, we
considered a ‘per protocol’ analysis, whereby only patients who were
actually receiving their assigned therapy at 6 months were included.
Examination of follow-up quality of life data obtained in May
2007 was undertaken for the 34 patients who were still alive and on
dialysis (Figure 1). Given that nearly 50% of patients were no longer
receiving the therapy they had been randomized to, follow-up data
are presented in a descriptive fashion to assess how quality of life
changed for patients remaining on nocturnal hemodialysis, or who
were subsequently converted from conventional hemodialysis to
nocturnal hemodialysis.
All statistical tests were two-sided and a P-value of o0.05 was
considered statistically significant. Comparison of normally dis-
tributed variables was performed using t-tests for independent
samples. Correction for multiple statistical tests was not undertaken
as these were secondary analyses of the randomized trial—as such,
these analyses should be considered exploratory. We also used
multilevel mixed effects models to test the independent association
between dialytic modality and longitudinal post-randomization EQ-
5D scores, after adjustment for prerandomization EQ-5D. All
statistical analyses were performed using STATA 10.0 software
(STATA Corporation, College Station, TX, USA). In addition to
statistical analyses, observed quality of life outcomes were compared
with benchmarks for minimal clinically important differences for
the different quality of life measures.
Although some of this quality of life data have been published
using a different presentation format (Figures 2a and 3),10 the
majority of the data presented herein have not been previously
published. Our intent in this article was to provide more data and
discussion with respect to the impact of nocturnal hemodialysis on
quality of life.
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